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Toshiyuki Shirai1, Koji Noda1, Keiichi Nakagawa2 and Tadashi Kamada1Abstract
Background: To moving lung tumors, we applied a respiratory-gated strategy to carbon-ion pencil beam scanning
with multiple phase-controlled rescanning (PCR). In this simulation study, we quantitatively evaluated dose distributions
based on 4-dimensional CT (4DCT) treatment planning.
Methods: Volumetric 4DCTs were acquired for 14 patients with lung tumors. Gross tumor volume, clinical target volume
(CTV) and organs at risk (OARs) were delineated. Field-specific target volumes (FTVs) were calculated, and 48Gy(RBE) in a
single fraction was prescribed to the FTVs delivered from four beam angles. The dose assessment metrics were
quantified by changing the number of PCR and the results for the ungated and gated scenarios were then compared.
Results: For the ungated strategy, the mean dose delivered to 95% of the volume of the CTV (CTV-D95) was in average
45.3 ± 0.9 Gy(RBE) even with a single rescanning (1 × PCR). Using 4 × PCR or more achieved adequate target coverage
(CTV-D95 = 46.6 ± 0.3 Gy(RBE) for ungated 4 × PCR) and excellent dose homogeneity (homogeneity index =1.0 ± 0.2%
for ungated 4 × PCR). Applying respiratory gating, percentage of lung receiving at least 20 Gy(RBE) (lung-V20) and heart
maximal dose, averaged over all patients, significantly decreased by 12% (p < 0.05) and 13% (p < 0.05), respectively.
Conclusions: Four or more PCR during PBS-CIRT improved dose conformation to moving lung tumors without gating.
The use of a respiratory-gated strategy in combination with PCR reduced excessive doses to OARs.
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Pencil-beam scanning carbon ion radiotherapy (PBS-
CIRT) has been recently implemented in our institution
and is being used for tumors not subject to respiratory
motion, such as those in the pelvic and head and neck
regions [1]. In contrast to the passive scattering beam
irradiation technique, the PBS-CIRT does not require
a compensating bolus or patient collimator. PBS-CIRT
generally requires much less time to start treatment
than passive beam therapy and is also useful for adap-
tive therapy such as re-planning during a course of
treatment. Nevertheless, a major limitation of this method* Correspondence: shinshin@nirs.go.jp
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unless otherwise stated.is the intra-/inter-fractional positional changes. The com-
plicated interplay effect between the beam spot and tumor
motion during treatment may result in dose degrad-
ation within the target and excessive doses to healthy
adjacent tissues if positional changes are not taken into
consideration.
One solution to the problem of delivering a prescribed
dose to a moving target is phase-controlled rescanning
(PCR) [2,3]. The effective use of PBS-CIRT for lung
treatment requires an initial quantitative evaluation of
the dose distribution by using lung 4-dimensional com-
puted tomography (4DCT) data sets. In this study, we
investigated the impact of PCR and intrafractional re-
spiratory motion on lung dose distribution in PBS-CIRT
and compared the results between ungated and gated
strategies.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients
Fourteen patients with lung tumors treated by CIRT in
our hospital were randomly selected. None were candi-
dates for surgical resection due to medical reasons or
patient refusal. All patients had stage I non-small cell
lung cancer (NSCLC) or oligometastatic lung tumors as
a single lesion. Patient characteristics are summarized in
Table 1.Image acquisition
After providing written informed consent, patients under-
went 4DCT under free-breathing conditions. 4DCT data
were acquired by using a 256 multi-slice CT, which can be
obtained approximately 13 cm in a single rotation, there-
fore, a single respiratory cycle was obtained during 4DCTTable 1 Patient characteristics





1 M 75 T2N0M0 5.8 4.1 Left upper
lobe
2 M 84 meta 3.0 3.9 Right upper
lobe
3 M 76 meta 7.2 3.8 Right lower
lobe
4 F 77 T2N0M0 4.0 3.3 Left upper
lobe
5 F 58 meta 0.8 4.0 Right lower
lobe
6 M 65 T2N0M0 33.4 4.3 Right lower
lobe
7 F 80 T2N0M0 13.1 4.2 Left upper
lobe
8 M 75 T2N0M0 8.0 3.1 Right lower
lobe
9 F 81 meta 0.9 2.7 Left upper
lobe
10 M 64 T2N1M0 31.1 4.4 Left upper
lobe
11 F 65 meta 10.8 5.5 Right lower
lobe
12 M 61 T1N0M0 5.0 3.6 Right lower
lobe
13 M 80 T1N0M0 5.0 3.4 Right middle
lobe
14 F 79 T1N0M0 2.2 2.8 Right lower
lobe
Average 72.9 9.3 3.8
S.D. 8.5 10.3 0.7
Abbreviations: ADC adenocarcinoma, Meta metastasis, SD standard deviation, SCC sq
COM 3-dimensional displacement of center of mass.
GTV-COM was calculated at the peak 3D distance using 4DCT data sets for all respiratory p
strategies, respectively.imaging [4]. All patients were fixed on the patient bed in
the supine or prone position using an immobilization de-
vice. The respiratory phase was monitored using a respira-
tory sensing system consisting of a position-sensitive
detector and an infrared-emitting light marker (Toyonaka
Kenkyujo, Osaka, Japan). For the reconstruction condi-
tions, the voxel size was 0.78 × 0.78 × 0.50 mm and the
4DCT data sets were subdivided into 10 phases (T00: peak
inhalation; T50: peak exhalation).Target definition
Gross tumor volume (GTV) and organs-at-risk (OARs),
including the normal bilateral lung (excluding the defined
GTV), spinal cord, and heart were manually delineated on
T50. These contours were transferred to the other phases









S4 SP ADC 3.4 × 3.2 × 1.7 1.0 × 1.1 × 1.4 0.2 × 0.2 × 0.4
S3 SP SCC 2.0 × 2.3 × 1.5 1.5 × 4.7 × 21.8 0.9 × 1.3 × 11.6
S6 PR meta 2.5 × 2.6 × 2.5 0.8 × 1.6 × 5.1 0.8 × 0.8 × 3.9
S3 SP SCC 2.5 × 2.8 × 1.4 1.4 × 1.7 × 5.8 0.5 × 0.8 × 2.1
S7 SP meta 1.3 × 1.2 × 1.1 0.8 × 3.1 × 11.9 0.8 × 0.8 × 3.4
S9 PR SCC 5.0 × 5.9 × 3.9 1.0 × 1.6 × 8.7 0.2 × 0.4 × 4.3
S3 SP ADC 3.7 × 3.7 × 3.2 2.0 × 2.6 × 6.9 0.5 × 0.3 × 3.6
S10 PR SCC 3.1 × 2.8 × 2.2 1.1 × 3.7 × 17.0 0.1 × 1.7 × 6.8
S3 SP meta 1.4 × 1.1 × 1.2 2.4 × 2.0 × 3.9 0.5 × 0.4 × 0.6
S4 SP SCC 4.8 × 4.7 × 4.9 0.7 × 1.6 × 2.3 0.7 × 0.7 × 0.5
S7 SP meta 2.7 × 3.0 × 2.8 1.1 × 1.5 × 2.1 0.7 × 1.8 × 0.4
S8 PR ADC 2.7 × 2.5 × 1.7 1.4 × 1.1 × 1.3 0.0 × 0.8 × 0.4
S5 SP ADC 3.0 × 2.6 × 2.4 2.2 × 1.0 × 0.8 2.2 × 0.0 × 0.9
S9 PR ADC 2.0 × 2.0 × 1.2 2.5 × 3.1 × 11.4 1.4 × 1.7 × 3.5
2.9× 2.9 × 2.3 1.4 × 2.2 × 7.2 0.7 × 0.8 × 3.0
1.1 × 1.3 × 1.1 0.6 × 1.1 × 6.4 0.6 × 0.6 × 3.1
uamous cell carcinoma, SP supine, PR prone, GTV gross tumor volume,
hases (10 phases) and the 3 phases around peri-exhalation for the ungated and gated
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10 mm margins to the GTVs in all directions, and then,
they were manually modified considering the distance
from the target to chest wall and ribs.
Since charged particle beams are highly sensitive to
geometrical variations in water-equivalent path length
(WEPL), intrafractional variations result in either over-
shooting or undershooting the target. To account for
these WEPL changes in all motion phases, the field-
specific target volume (FTV) was designed using 4DCT
data sets [6]. To account for intrafractional WEPL varia-
tions at the distal and proximal sides along the same
ray-line at respective phases, the FTV for each beam dir-
ection was constructed by selecting the maximum and
minimum WEPL values. Two types of FTV were calcu-
lated, the first using CTVs around exhalation (T40-T60)
(FTVgated) and the second using CTVs around a full
respiratory cycle (T00-T90) (FTVungated).
Treatment planning
4D treatment planning was performed using 4DCT data
in respective respiratory phases. Using single uniform
field optimization, the FTV was enclosed at minimum
by the 95% isodose line for the patient’s dose prescrip-
tion. In accordance with our routine lung treatment
protocol, 48Gy(RBE) in a single fraction was delivered
via four beam angles from the ipsilateral side of the
tumor [7].
A reference dose distribution (planning dose) was
calculated based on a FTV created spot map from the
4DCT data set. The spots were equally distributed over
all phases in order to avoid the interplay effect. In
addition, dose distributions in each of the respective
phases were calculated using 4DCT data sets for PCR at
respective beam spot positions by considering dose rate,
energy change time, and respiratory cycles. The accumu-
lated dose distribution was then calculated (treatment
dose) by using DIR, which transforms the respective
phase doses to the reference phase (T50) [5]. Our DIR
accuracy averaged over all patients was 0.9 ± 1.4 mm,
which was derived from the 4DCT data using the man-
ual point matching method. The beam weight maps for
the respective FTVs were optimized to obtain the uni-
form relative biological effectiveness (RBE) weighted
absorbed dose, which was calculated by considering
the non-linearity of RBE based on an experimental
study [8]. The number of rescannings was varied from
1 to 10 [2,3]. The starting phase of irradiation was T00
in the ungated strategy and T40 in the gated strategy.
All beam spots of a layer were designed to be irradi-
ated n times repeatedly within a single gating window.
After finishing one layer, the energy was changed to
irradiate the next proximal layer during the next gating
window. Scanning beam irradiation time was longerthan that for treatment planning CT acquisition. Therefore,
when the accumulated dose was calculated, we assumed
that the respiratory data of respective patients were
repeated during scanning beam irradiation.
In our institution, PBS-CIRT is delivered using a range
shifter and 11 synchrotron energies resulting in what we
term hybrid depth scanning [9]. Beam spot positions
and beam weights were optimized for the FTV. Spot
spacing was 2.0 mm laterally and 3.0 mm in the beam
direction, and lateral scatter (80-20%) was approximately
5.0 mm. Control times for the range shifter and synchro-
tron energy changes were 420 ms and 150 ms, respect-
ively. We set the scanning speeds in the superior-inferior
and left-right directions to 100 mm/ms and 50 mm/ms,
respectively, and the scan path was optimized to minimize
the total path length.
The results were then compared for the ungated and
gated strategies. We assumed that the respiratory pattern
remained unchanged throughout the treatment course.
Dose-volume histograms (DVH) for the CTV and OARs
at peak exhalation were calculated for both plans. The
minimum/maximum dose (Dmin/max) and the dose
delivered to 95% of the volume (D95) of the CTV were
calculated at the reference phase. To evaluate the dose
homogeneity, a dose homogeneity index (HI) was defined
as the standard deviation (SD) of the dose voxel values
within the CTV at the reference phase to the prescribed
dose. For all OARs, the mean, maximum, and minimum
doses were evaluated. The derived dosimetric parameters
were averaged over all patients and their SD was calcu-
lated. The Wilcoxon signed-rank test was used to examine
the differences in dose assessment metrics. For multiple
comparisons, the Steel-Dwass test was performed. A prob-
ability value of less than 0.05 was considered to be signifi-
cant. All 4D dose distributions were analyzed using the
Aqualyzer system [10].
Results
The upper panels in Figure 1 give the accumulated dose
distributions with a single beam angle when the number of
rescannings was varied without respiratory gating (Figure 1a).
The treatment dose differed from the planning dose distri-
bution due to intrafractional motion. Target dose conform-
ation improved with an increasing number of PCR. In a
typical case, patient no. 7, for example, D95 values were
44.4 Gy(RBE), 46.7 Gy(RBE), and 46.7 Gy(RBE) with 1×, 4×
and 8 × PCR, respectively. Furthermore, as shown in the
lower panels of Figure 1b, the gating strategy achieved good
dose conformation to the target even when the number of
PCR was small; D95 with 1 × PCR in the gated plan
(45.7 Gy(RBE)), for example, was better than that in the
ungated plan (44.4 Gy(RBE)).
Dose assessment values averaged for all patients are sum-
marized in Figure 1c-f. CTV coverage improved gradually
Figure 1 (See legend on next page.)
Takahashi et al. Radiation Oncology 2014, 9:238 Page 4 of 9
http://www.ro-journal.com/content/9/1/238
(See figure on previous page.)
Figure 1 Carbon-ion dose distributions with a single beam angle for (a) ungated and (b) gated irradiation. Planning dose distribution
and treatment dose simulations with 1 × PCR, 4 × PCR, and 8 × PCR. In the supine position, the beam angle was set to 340 degrees. The
respiratory cycle was 4.2 sec. Yellow lines demonstrate the CTV (patient no. 7). Green arrows show beam direction. In Figure 1(a), white arrow
shows the dose degradation in the CTV. Dose assessment metrics for all 14 cases as a function of the number of rescannings. Beam angle was
340 degrees. D95, Dmax, and Dmin for (c) ungated and (d) gated strategies. The homogeneity index (HI) is for (e) ungated and (f) gated strategies.
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ungated and gated strategies. Although the gated
strategy reduced the impact of the interplay effect by
minimizing intrafractional tumor motion, four or more
PCR were necessary to obtain the same results as the
planning dose. Results are summarized in Table 2.
Figure 2 gives the dose distributions of a four-field
plan for the same case. Without gating and a low num-
ber of PCR (e.g. 1 × PCR), the use of multiple coplanar
fields reduced hot and cold spots and provided better
conformation to the CTV than the single field men-
tioned above. D95, Dmax and Dmin values of the CTV
improved with the use of multiple fields, from 44.4 Gy
(RBE), 53.3 Gy(RBE), and 43.7 Gy(RBE) with a single
field to 46.2 Gy(RBE), 49.9 Gy(RBE), and 45.1 Gy(RBE)
with four fields, respectively. Moreover, the addition of
gating provided better dose volume indices for the CTV
than with the ungated plans. This tendency was particularlyTable 2 Dose assessment metrics averaged for all patients for 1 ×
No. beam
fields
Metrics Strategy Planning dose 1×PCR
Mean± (SD) Range Mean±
1 beam field D95 (Gy(RBE)) Ungated 46.5 ± 0.4 (45.6-47.4) 43.7 ± 1
Gated 46.1 ± 0.6 (44.8-47.4) 45.4 ± 0
Dmax (Gy(RBE)) Ungated 48.7 ± 0.3 (48.5-49.4) 56.6 ± 4
Gated 48.9 ± 0.3 (48.5-49.4) 51.7 ± 1
Dmin (Gy(RBE)) Ungated 43.4 ± 1.8 (39.4-47.5) 39.8 ± 3
Gated 43.3 ± 1.4 (39.8-47.0) 42.0 ± 1
HI (%) Ungated 1.1 ± 0.2 (0.5-1.7) 5.1 ± 2.3
Gated 1.3 ± 0.4 (0.6-2.1) 2.5 ± 0.8
Treatment time (s) Ungated N/A N/A 99.1 ± 5
Gated N/A N/A 118.5 ±
4 beam fields D95 (Gy(RBE)) Ungated 46.7 ± 0.4 (46.0-47.6) 45.3 ± 0
Gated 46.3 ± 0.5 (45.5-47.6) 46.1 ± 0
Dmax (Gy(RBE)) Ungated 48.5 ± 0.1 (48.5-49.0) 52.6 ± 2
Gated 48.6 ± 0.2 (48.5-49.0) 49.8 ± 0
Dmin (Gy(RBE)) Ungated 44.2 ± 1.7 (40.3-47.5) 42.7 ± 1
Gated 44.4 ± 1.1 (42.7-47.5) 44.0 ± 0
HI (%) Ungated 0.9 ± 0.2 (0.3-1.2) 2.9 ± 1.1
Gated 1.1 ± 0.3 (0.3-1.6) 1.5 ± 0.3
Treatment time (s) Ungated N/A N/A 396.4 ±
Gated N/A N/A 474.1 ±
Abbreviations: CTV clinical target volume, HI homogeneity index, PCR phase-controlled rescobvious with a single port with 1 × PCR (Figure 1), but the
magnitude of improvement in dose uniformity became less
prominent with 4× and 8 × PCR (Figure 1) and with four
beam angles (Figure 2). With four beam fields using the
gated strategy, an increase in PCR frequency provided only
a slight improvement in dose metrics, with D95 of the
CTV being 46.3 Gy(RBE), 46.4 Gy(RBE), and 46.4 Gy(RBE)
for 1×, 4× and 8 × PCR, respectively.
Dose assessment values averaged for all patients for
the four-field treatment are summarized in Figure 2c-f.
In particular, four or more PCR resulted in adequate tar-
get coverage (CTV-D95: 45.3 ± 0.9 Gy(RBE) for 1 × PCR;
46.6 ± 0.3 Gy(RBE) for 4 × PCR; and 46.7 ± 0.4 Gy(RBE)
for 8 × PCR in the ungated strategy) and a better HI
(2.9 ± 1.1% for 1 × PCR; 1.0 ± 0.2% for 4 × PCR; and 0.9 ±
0.2% for 8 × PCR in the ungated strategy). As shown in
Table 2, as for D95 for 4 × PCR/8 × PCR, applying the
gated strategy induced a slight decrease but its extent wasPCR, 4 × PCR, and 8× PCR
4×PCR 8×PCR
(SD) Range Mean± (SD) Range Mean± (SD) Range
.7 (39.0-46.2) 46.3 ± 0.4 (45.4-47.2) 46.5 ± 0.4 (45.6-47.3)
.7 (42.7-46.8) 45.9 ± 0.5 (44.7-46.8) 46.1 ± 0.6 (44.7-47.2)
.7 (50.4-73.0) 49.7 ± 0.6 (49.0-50.9) 49.0 ± 0.3 (48.5-49.9)
.9 (49.0-55.2) 49.9 ± 1.0 (48.5-53.8) 49.3 ± 0.5 (49.0-50.9)
.0 (33.1-44.2) 43.0 ± 1.9 (38.4-46.6) 43.3 ± 1.8 (39.4-47.5)
.6 (36.0-45.1) 42.8 ± 1.3 (39.4-46.6) 43.2 ± 1.3 (39.8-47.0)
(2.0-12.4) 1.4 ± 0.3 (0.7-2.3) 1.2 ± 0.2 (0.6-1.7)
(1.3-4.4) 1.7 ± 0.3 (1.0-2.6) 1.5 ± 0.4 (0.7-2.1)
0.7 (28.3-251.1) 99.1 ± 50.7 (28.3-251.1) 99.1 ± 50.7 (28.3-251.1)
55.0 (44.3-253.9) 118.8 ± 55.0 (47.1-269.8) 119.6 ± 55.5 (44.9-264.3)
.9 (43.0-46.3) 46.6 ± 0.3 (46.2-47.5) 46.7 ± 0.4 (46.0-47.6)
.4 (45.6-46.8) 46.2 ± 0.4 (45.6-47.2) 46.3 ± 0.6 (45.5-47.5)
.2 (49.9-56.2) 48.9 ± 0.3 (48.5-49.4) 48.6 ± 0.2 (48.5-49.0)
.8 (49.0-50.9) 49.0 ± 0.5 (48.5-50.4) 48.8 ± 0.3 (48.5-49.4)
.8 (39.4-45.1) 44.2 ± 1.7 (40.3-47.5) 44.2 ± 1.6 (40.8-47.5)
.7 (43.2-46.1) 44.2 ± 0.8 (43.2-46.6) 44.3 ± 1.1 (42.7-47.5)
(1.5-5.6)) 1.0 ± 0.2 (0.4-1.2) 0.9 ± 0.2 (0.3-1.2)
(1.1-2.0)) 1.2 ± 0.2 (0.7-1.6) 1.2 ± 0.3 (0.4-1.7)
195.4 (180.7-915.8) 396.4 ± 195.4 (180.7-915.8) 396.4 ± 195.4 (180.7-915.8)
218.6 (235.1-939.1) 475.1 ± 218.7 (234.5-960.6) 478.5 ± 220.2 (239.2-956.7)
anning, SD standard deviation.
Figure 2 (See legend on next page.)
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Figure 2 Carbon-ion dose distributions with four beam angles for (a) ungated and (b) gated irradiation. Planning dose distribution and
accumulated dose simulations with 1 × PCR, 4 × PCR, and 8 × PCR. In the supine position, the beam angle was set to 20, 70, 110, and 340
degrees. The respiratory cycle was 4.2 sec. Yellow lines demonstrate the CTV (patient no. 7). Green arrows show beam direction. Dose assessment
metrics for all 14 cases as a function of the number of rescannings. D95, Dmax, and Dmin for (c) ungated and (d) gated strategies. The
homogeneity index (HI) is for (e) ungated and (f) gated strategies.
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48 Gy(RBE)). In contrast, the dose coverage for 1 × PCR
was significantly lower than for 4× and 8 × PCR (CTV-
D95, Dmax, and HI; Steel-Dwass test, all p <0.01) in the
ungated strategy. 1 × PCR in the ungated plan was not
enough to sufficiently reduce dose inhomogeneity, and
Dmax/Dmin values for all patients reached 52.6 Gy(RBE)/
42.7 Gy(RBE). With regard to OARs, significant sparing of
healthy tissues was achieved under all the modes studied.
Of particular note is that the gated strategy decreased the
dose to normal surrounding tissues. The mean percentage
of lung receiving at least 20 Gy(RBE) (lung-V20) value and
heart Dmax with 1 × PCR significantly decreased by 12%
(from 4.3% in the ungated strategy to 3.8% in the gated
strategy, p <0.001) and 13% (from 7.8 Gy(RBE) in the
ungated strategy to 6.8 Gy(RBE) in the gated strategy,
p = 0.01), respectively. Further, lung-V20, and heart
and spinal cord Dmax indices did not change with an
increase in the number of PCR.
With the PCR method, the total time of dose delivery
is basically the same because each layer is irradiated dur-
ing a single gate window (Table 2). However, total irradi-
ation times with gated plans are necessarily prolonged.
Discussion
In this study, we evaluated 4D dose distributions with
changes in the number of PCR (1 to 10 times) using
4DCT datasets for 14 patients with lung tumors, and
compared results between ungated and gated strategies.
Although several groups have introduced rescanning
and gating strategies [11,12], specifications of their beam
delivery systems and rescanning methods (layered or
volumetric etc.) differed from those of the presented
study. In order to simulate lung PBS-CIRT delivery, we
calculated FTVs that take into account intrafractional
range variations using 4DCT data for the dose prescrip-
tion. For the 4D treatment planning, dose distribution
was calculated as a function of each respiratory phase,
and the accumulated dose was calculated by applying
DIR. From this we determined that four or more PCR
would provide acceptable dose conformity, independent
of patient condition (tumor location/size and respiratory
cycle, etc.). This simple approach can be easily inte-
grated into clinical applications.
Knopf et al. reported that using multiple scanning
beam directions improved dose homogeneity in three
patients with liver conditions [11]. As shown in Table 2,improved dose coverage for the CTV (D95 ≥ 43.0 Gy
(RBE) for all patients) was achieved even though neither
gating nor rescanning were applied because four field
plans were used and the averaging of multiple beam
angles (Figures 1 and 2) improved dose conformation.
Thus, multiple beam directions will be used in the scan-
ning beam lung treatment based on our lung treatment
protocol used in the passive beam treatment [7].
Kang et al. used an average CT approach to the
moving target and succeeded in delivering the beam to
lung tumors using a commercially available treatment
planning system [13]. As their methods used a smeared
beam field and virtual target density estimation within
the target, intrafractional range variations were not fully
considered. In contrast, we used the T50-4DCT image
as a reference, and the respiratory gating window was
set to peri-exhalation because the peak exhalation is the
most stable and reproducible respiratory phase.
Based on these FTV settings, we then analyzed the
effectiveness of increasing PCR frequency. With an
adequate number of rescannings, PCR averaged out the
interplay effect between beam spot and intrafractional
motion. Four or more PCR improved dose homogeneity
to the moving target. This study therefore confirmed
our previous observations in a numerical phantom [3].
Further more than 4 × PCR did not substantially
improve target coverage and homogeneity as can be seen
from Figures (Figures 1c-f, 2c-f). This plateau can be ex-
plained as follows; 4 × PCR provides adequate averaging
out of the interplay effect and further rescanning pro-
vides no additional improvement in dose conformation.
Furthermore, beyond the number of PCR, the additional
averaging effect improves dose conformation via several
other mechanisms. During PCR to one layer, the scan
trajectory inverts after each single scan of an iso-energy
layer. Further, during the peak expiratory phase (T50)
the direction of respiratory tumor motion is reversed
due to the switch from the inspiratory to expiratory
phase.
The effect of an increase in PCR on dose metrics was
larger for the ungated than for the gated strategy
because gating itself causes an improvement in dose
homogeneity by minimizing the amplitude of motion
(Figures 1e,f, 2e and f ).
For all CTV metrics listed in Table 2, the gated strat-
egy was clearly superior to the ungated strategy with 1 ×
PCR. This does not mean that the gating method can
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tion exists within the shrunken FTV, and the interplay ef-
fect between the beam spot and tumor motion during the
gating window leads to dose inhomogeneity with 1 × PCR
(much slow scanning speed), even with gating. This is em-
phasized with a single beam angle. The multiple PCR
technique should therefore be used regardless of whether
the ungated or gated strategy is used.
Several limitations of our study warrant mention. First,
we assumed that respiratory patterns during the treat-
ment planning CT and actual treatment were regular
and identical. PCR parameters (dose rate for respective
iso-layers, sweeper speed, spot position/trajectory etc.)
are calculated from the gating window time and are sent
to the irradiation machine before the delivery of each
layer. Therefore, once the irradiation is started, the irradi-
ation pattern cannot be changed even though the patient’s
respiratory pattern may change. The implementation of
countermeasures to irregular respiratory patterns was be-
yond the scope of the present study, but will be evaluated
in future studies.
Second, like most simulation studies using 4DCT data,
we assumed that zero motion between the respective
phases of the 4DCT. That is, all calculations assumed
the tumor is static within each phase and then instant-
aneously moves to the new position in the subsequent
phase. Although with two-dimensional phantom study,
we have previously confirmed its continuity [2].
Third, the respiratory phase that is determined with a
non-invasive surrogate marker is not always consistent
with the movement of the in-treatment tumor location.
In the ongoing development of this treatment protocol,
the use of fluoroscopy might allow more precise moni-
toring of the tumor position during treatment and it
might also allow “amplitude-based gated irradiation”
[14]. The evaluation of possible interplay effects with
this new gating strategy must be carried out and will be
addressed in a future study.
Conclusions
PBS-CIRT with four or more PCR should substantially
improve the accuracy of dose delivery for lung tumors,
and bring it close to that of the planning dose distribu-
tion. In addition the use of gating reduces the residual
motion and also reduces the FTV size leading to better
sparring of healthy tissue while keeping the same tumor
coverage. For practical treatment considerations, we do
not presently calculate 4D dose distributions that in-
clude the interplay effect in our routine treatment work-
flow because of the costs imposed by the substantial
data volume and computing time. Moreover, no com-
mercial treatment planning system provides this type of
dose calculation. The planning dose approach can there-
fore be integrated into routine treatment protocols inplace of a complete 4D dose calculation provided that
the shown approach of gating, PCR (at least four times)
and if possible the usage of multiple beam ports is con-
ducted. This simulation study provides valuable informa-
tion prior to the start of PBS-CIRT in patients suffering
from lung tumors.
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